Sagimet to Present Phase 2b Data Showing 26-Week Bile Acid Reductions in MASH
Sagimet Biosciences will present Phase 2b FASCINATE-2 trial data at the Keystone Symposium, showing histological responders to denifanstat saw significant reductions in glycine- and taurine-conjugated bile acids at 26 weeks. The board granted 9,600 options to a new hire under Nasdaq Rule 5635(c)(4) with a four-year vesting schedule.
1. Phase 2b Data Presentations
Sagimet will deliver both a poster and an oral presentation at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium in Vancouver on April 12–15, 2026. Senior Director Wen-Wei Tsai, Ph.D., will detail how denifanstat-treated histological responders in the FASCINATE-2 trial exhibited significant reductions in plasma glycine- and taurine-conjugated bile acids at 26 weeks.
2. Inducement Grant Details
On April 3, 2026, the Compensation Committee approved an inducement grant of 9,600 stock options to a newly hired employee under Nasdaq Rule 5635(c)(4). The options carry a ten-year term, an exercise price equal to the closing price on April 2, 2026, and vest 25% after one year with the balance monthly over the following 36 months, subject to continued service.
3. Biomarker and Pipeline Implications
The observed bile acid reductions correlated with fibrosis regression and MASH resolution suggest these conjugated bile acids may serve as response biomarkers for denifanstat. Denifanstat’s positive Phase 2b results reinforce its clinical profile ahead of planned combination and Phase 3 studies, while a second oral FASN inhibitor remains in Phase 1 testing.